glp-1 therapies success rate Drugs Market Size to Hit USD 132.79 Bn by 2035 GLP-1 Agonists Weight Loss Drugs

She highlighted the differences in and analysis of the oral GLP-1 RAs approved for obesity management, semaglutide and orforglipron, as well as emerging formulations, including CagriSema, a combination of semaglutide and cagrilintide

Heres what to keep in mind: No real GLP-1 drugs inside

Heres what might be happening behind the scenes: Dry mouth (xerostomia): Dehydration is common, especially during the early stages of treatment

Many patients report a reduction in appetite and improved blood sugar control within this time frame, which can lead to gradual weight loss

Underlying pattern loss is stable or being managed

WHO guideline on the use of glucagon-like peptide-1 (GLP-1) therapies for the treatment of obesity in adults